| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
DPP-4 (dipeptidyl aminopeptidase 4)
Dipeptidyl peptidase-4 (DPP-4). Sitagliptin fenilalanil hydrochloride is a DPP-4 inhibitor, blocking the enzyme responsible for the rapid degradation of the incretin hormones GLP-1 and GIP. |
|---|---|
| ln Vitro |
No specific in vitro activity data for this derivative are detailed in supplier literature. The parent compound sitagliptin potently inhibits DPP-4 with an IC50 of approximately 18 nM. As a DPP-4 inhibitor, it prevents the cleavage of GLP-1 and GIP, thereby increasing their half-life and potentiating glucose-dependent insulin secretion.
|
| ln Vivo |
The parent compound sitagliptin is clinically validated in vivo as an oral antidiabetic agent. It improves glycemic control by increasing active GLP-1 levels, leading to enhanced insulin secretion, reduced glucagon release, and decreased hepatic gluconeogenesis. The derivative is expected to exhibit similar pharmacological effects.
|
| Enzyme Assay |
Sitagliptin fenilalanil hydrochloride, as a DPP-4 inhibitor, can be evaluated using cell-free fluorometric assays. Human recombinant DPP-4 enzyme is incubated with a fluorogenic substrate such as Gly-Pro-AMC. The inhibitor is added at varying concentrations, and the reaction is monitored at excitation 360 nm and emission 460 nm. A decrease in fluorescence indicates DPP-4 inhibition, and the IC50 is calculated from dose-response curves.
|
| Cell Assay |
Cellular assays utilize cell lines such as Caco-2 or differentiated 3T3-L1 adipocytes that express DPP-4 on their surface. Cells are treated with Sitagliptin fenilalanil hydrochloride for 1-2 hours, and DPP-4 activity is measured in cell lysates or on cell surfaces using a fluorogenic substrate. The inhibition of DPP-4 activity confirms the compound's ability to engage its target in a relevant cellular context.
|
| Animal Protocol |
In vivo experiments involve the oral administration of Sitagliptin fenilalanil hydrochloride to rodent models of type 2 diabetes, such as db/db mice or high-fat diet-fed rats. Blood samples are collected pre-dose and at various time points post-dose. Plasma DPP-4 activity is measured, and the oral glucose tolerance test (OGTT) is performed to assess the compound's effect on glucose excursion, insulin, and active GLP-1 levels.
|
| ADME/Pharmacokinetics |
Sitagliptin fenilalanil hydrochloride is an orally bioavailable small molecule. The parent sitagliptin is well-absorbed, with an oral bioavailability of approximately 87% in humans. It is minimally metabolized by CYP3A4 and CYP2C8 and is primarily excreted unchanged in the urine, with a terminal half-life of approximately 12 hours. The derivative is expected to have similar PK properties.
|
| Toxicity/Toxicokinetics |
The parent drug sitagliptin has a well-established safety profile in humans, with gastrointestinal side effects (nausea, diarrhea) being the most common. Pancreatitis and severe arthralgia are rare adverse events. Toxicological data for the fenilalanil hydrochloride derivative are not extensively reported. As a research compound, standard laboratory precautions should be followed.
|
| References | |
| Additional Infomation |
This compound is a derivative of the FDA-approved DPP-4 inhibitor sitagliptin, which is indicated for type 2 diabetes as monotherapy or combination therapy with metformin. The fenilalanil hydrochloride derivative is a research-grade compound and has not received regulatory approval. Its primary use is as a tool in metabolic research, often employed in preclinical studies alongside other DPP-4 inhibitors for comparative analysis.
|
| Molecular Formula |
C25H25CLF6N6O2
|
|---|---|
| Molecular Weight |
590.95
|
| Exact Mass |
590.163
|
| CAS # |
1339954-75-4
|
| Related CAS # |
Sitagliptin fenilalanil;1339955-03-1
|
| PubChem CID |
168265396
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
40
|
| Complexity |
846
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(C1=NN=C2CN(CCN21)C(=O)C[C@H](NC(=O)[C@@H](N)CC1C=CC=CC=1)CC1C=C(C(=CC=1F)F)F)(F)(F)F.Cl
|
| InChi Key |
LZDQVWZJBLFZSN-PXPMWPIZSA-N
|
| InChi Code |
InChI=1S/C25H24F6N6O2.ClH/c26-17-12-19(28)18(27)10-15(17)9-16(33-23(39)20(32)8-14-4-2-1-3-5-14)11-22(38)36-6-7-37-21(13-36)34-35-24(37)25(29,30)31;/h1-5,10,12,16,20H,6-9,11,13,32H2,(H,33,39);1H/t16-,20+;/m1./s1
|
| Chemical Name |
(2S)-2-amino-N-[(2R)-4-oxo-4-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-1-(2,4,5-trifluorophenyl)butan-2-yl]-3-phenylpropanamide;hydrochloride
|
| Synonyms |
Sitagliptin fenilalanil hydrochloride; 1339954-75-4; Sitagliptin fenilalanil (hydrochloride); HY-147401A; DA-77863; CS-0676211; (2S)-2-amino-N-[(2R)-4-oxo-4-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-1-(2,4,5-trifluorophenyl)butan-2-yl]-3-phenylpropanamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (42.30 mM )
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6922 mL | 8.4610 mL | 16.9219 mL | |
| 5 mM | 0.3384 mL | 1.6922 mL | 3.3844 mL | |
| 10 mM | 0.1692 mL | 0.8461 mL | 1.6922 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
